NewAmsterdam Pharma Co. Hits New 52-Week High of USD 31.81

NewAmsterdam Pharma Co. NV has reached a significant milestone by hitting a new 52-week high of USD 31.81 on October 3, 2025. This achievement underscores the company's notable performance in the pharmaceuticals and biotechnology sector, particularly as it has recorded a remarkable 55.84% increase over the past year, significantly outpacing the S&P 500's 17.82% performance during the same period.
With a market capitalization of USD 2,826 million, NewAmsterdam Pharma is classified as a small-cap company. Despite its growth, the company remains in a loss-making position, reflected in its price-to-earnings ratio, which is not applicable. The stock's price-to-book ratio stands at 3.63, indicating how the market values the company's equity relative to its book value.

Additionally, NewAmsterdam Pharma's debt-to-equity ratio is reported at -0.95, and its return on equity is -17.87%. The company does not offer a dividend yield, which is consistent with many firms in the early stages of growth in the biotechnology industry. This recent high marks a pivotal moment for NewAmsterdam Pharma as it continues to navigate the competitive landscape of its industry.